Showing results (1-10 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 23, 2022
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Investigational New Drugs|September 24, 2022
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsyShinsuke Ogusu, Ryo Ariyasu, Takahiro Akita, et al.
Investigational New Drugs|January 1, 1985
Radioimmunoassay for mitoxantrone, a new antitumor agentG Nicolau, V Szucs-Myers, W McWilliams, et al.
Investigational New Drugs|November 5, 2022
Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrenceYusuke Shima, Yuki Sato, Takeshi Morimoto, et al.
Investigational New Drugs|October 13, 2022
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancerToshiyuki Sumi, Yuta Koshshino, Motoki Sekikawa, et al.
Investigational New Drugs|November 4, 2022
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumorsShubham Pant, Tomislav Dragovich, Christopher Lieu, et al.
Investigational New Drugs|December 9, 2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasiaOlatoyosi Odenike, Anna Halpern, Lucy A Godley, et al.
Investigational New Drugs|December 1, 2014
Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangementYasuto Yoneshima, Isamu Okamoto, Masako Arimura-Omori, et al.
Investigational New Drugs|December 20, 2014
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemiasR Tibes, K T McDonagh, L Lekakis, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Pageof 372